Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone for Primary Aldosteronism (Exploratory Single-Arm Study)
jRCTs061250034Recruiting
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of finerenone in primary aldosteronism (PA). Primary endpoints: Plasma renin activity at 4 weeks and Plasma renin activity at 12 weeks. Started Nov 2025; status: recruiting.
02
Drugs
finerenone
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on jRCTs061250034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061250034.